1)Ambati BK, Nozaki M, Singh N et al:Corneal avascularity is due to soluble VEGF receptor-1. Nature 443:993-997, 2006
2)Pélez-Santonja JJ, Campos-Mollo E, Lledo-Riquelme M et al:Inhibition of corneal neovascularization by topical bevacizumab(anti-VEGF)and sunitinib(anti-VEGF and anti-PDGF)in an animal model. Am J Ophthalmol 150:519-528, 2010
3)Zhou Z, Apte SS, Soininen R et al:Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase Ⅰ. Proc Natl Acad Sci USA 97:4052-4057, 2000
4)Kato T, Kure T, Chang JH et al:Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett 508:187-190, 2001
5)Kure T, Chang JH, Kato T et al:Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice. Invest Ophthalmol Vis Sci 44:137-144, 2003
6)Eriksson K, Magnusson P, Dixelius J et al:Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 536:19-24, 2003
7)Chang JH, Javier JA, Chang GY et al:Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XⅧ collagen. FEBS Lett 579:3601-3606, 2005
8)Wu PC, Yang LC, Kuo HK et al:Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis 11:28-35, 2005